Skip to main content

Table 3 Most common TEAEs by grade

From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

TEAE occurring in >10% of patients, n (%)a

NCI CTCAE grade (n = 104)

Total

1

2

3

4

5

Any AE

104 (100.0)

8 (7.7)

37 (35.6)

37 (35.6)

13 (12.5)

8 (7.7)

Muscle spasms

74 (71.2)

45 (43.3)

23 (22.1)

6 (5.8)

0

0

Alopecia

69 (66.3)

49 (47.1)

20 (19.2)

NA

NA

NA

Dysgeusia

58 (55.8)

32 (30.8)

26 (25.0)

NA

NA

NA

Weight decreased

54 (51.9)

29 (27.9)

16 (15.4)

9 (8.7)

NA

NA

Fatigue

45 (43.3)

33 (31.7)

7 (6.7)

4 (3.8)

1 (1.0)

0

Nausea

34 (32.7)

25 (24.0)

9 (8.7)

0

0

0

Decreased appetite

29 (27.9)

19 (18.3)

7 (6.7)

3 (2.9)

0

0

Diarrhea

28 (26.9)

20 (19.2)

5 (4.8)

3 (2.9)

0

0

Constipation

20 (19.2)

14 (13.5)

6 (5.8)

0

0

0

Cough

20 (19.2)

16 (15.4)

4 (3.8)

0

NA

NA

Vomiting

18 (17.3)

15 (14.4)

3 (2.9)

0

0

0

Arthralgia

17 (16.3)

12 (11.5)

4 (3.8)

1 (1.0)

0

0

Headache

15 (14.4)

12 (11.5)

3 (2.9)

0

NA

NA

Nasopharyngitis

13 (12.5)

11 (10.6)

2 (1.9)

0

0

0

SCC

12 (11.5)

3 (2.9)

5 (4.8)

3 (2.9)

0

0

Ageusia

12 (11.5)

8 (7.7)

4 (3.8)

NA

NA

NA

Hypogeusia

11 (10.6)

10 (9.6)

1 (1.0)

NA

NA

NA

Pruritus

11 (10.6)

8 (7.7)

2 (1.9)

1 (1.0)

NA

NA

Dyspepsia

11 (10.6)

8 (7.7)

3 (2.9)

0

NA

NA

  1. AE adverse event, NA not applicable, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, SCC squamous cell carcinoma, TEAE treatment-emergent adverse event
  2. aMedical Dictionary for Regulatory Activities–preferred term